You just read:

Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019

News provided by

Eisai Inc.

Sep 24, 2019, 08:08 ET